DDInter1233 DDInter782
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Mitotane {u} (Compound) downregulates {v} (Gene) PEG10
Mitotane {u} (Compound) causes {v} (Side Effect) Digestion impaired
Mitotane (Compound) resembles Carbinoxamine (Compound)
Mitotane (Compound) binds CYP11B1 (Gene)
Mitotane (Compound) upregulates ADGRE5 (Gene)
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Mitotane (Compound) downregulates PEG10 (Gene)
Mitotane (Compound) causes Digestion impaired (Side Effect)